Business context and reporting period
Novelos Therapeutics, Inc. filed this unaudited Form 10-Q for the quarter ended March 31, 2012. The filing metadata identifies Cellectar Biosciences, but the registrant named in the filing is Novelos Therapeutics, Inc. Following its April 2011 acquisition of Cellectar, the company’s reporting focus shifted to Cellectar’s cancer-targeted compounds; development of Novelos’s NOV-002 and NOV-205 programs was suspended. The acquisition was accounted for as a reverse acquisition, so first-quarter 2011 results represent historical Cellectar, while first-quarter 2012 results include the combined company.
Financial results and liquidity
| Metric | Q1 2012 | Q1 2011 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $1.328 million | $471,404 |
| General and administrative expense | $997,671 | $131,726 |
| Total operating costs and expenses | $2.326 million | $853,564 |
| Net loss | $2.357 million | $965,252 |
| Basic and diluted loss per share | $0.06 | $0.08 |
| Cash used in operating activities | $1.703 million | $324,566 |
At March 31, 2012, cash and cash equivalents were $3.788 million, restricted cash was $55,000, and total current assets were $4.026 million. Cash declined $1.718 million from year-end 2011. Total assets were $8.649 million; total liabilities were $1.087 million, including $450,000 of long-term notes payable and approximately $5,782 of capital lease obligations. The filing reports no product revenue; profit and operating margins are therefore not meaningful.
Management cited $33.837 million of accumulated deficit and expects continuing operating losses. It estimated that available cash would fund operations only into the middle of the third quarter of 2012. The company reported no material income-tax provision or benefit. Stock-based compensation was $417,353 in Q1 2012, compared with $58,462 in Q1 2011.
Material changes versus the prior comparable period
- R&D expense rose approximately $857,000, or 181.9%, primarily as research and manufacturing activities resumed and costs increased for ongoing LIGHT and HOT clinical trials, personnel, stock compensation, patents, and facilities.
- G&A expense rose approximately $866,000, or 656.1%, reflecting added personnel and compensation, stock-based compensation, professional and public-company costs, insurance, rent, and travel.
- Merger costs fell from $250,434 in Q1 2011 to zero in Q1 2012. Grant income of $44,479 recorded in Q1 2011 did not recur. Q1 2012 included a $28,846 loss from revaluing derivative warrants.
- Net loss increased, while reported loss per share decreased from $0.08 to $0.06; weighted-average shares rose to 36.9 million from 12.8 million. Comparisons are affected by the reverse acquisition and the different underlying reporting entities.
Outlook, risks, contingencies, and unusual items
- Funding: The company filed an S-1 on April 9, 2012 for a potential unit offering of up to $10 million gross. It was not yet effective, and there was no assurance that the offering would proceed or raise funds. Management said it was pursuing financing alternatives; continued operations beyond its cash runway depend on additional funding.
- Programs: LIGHT (I-124-CLR1404) was in investigator-sponsored Phase 1-2 imaging trials, and HOT (I-131-CLR1404) was in a Phase 1b dose-escalation trial. Subject to funding, management expected HOT Phase 2 trials to begin in Q1 2013. COLD remained preclinical. These are forward-looking plans, not assured outcomes.
- Clinical and business risk: The company had no product revenue and warned that candidates could fail in testing, regulatory approval could be delayed or denied, and the company might be unable to obtain financing, manufacturing, or commercial partners. Additional equity or debt could dilute shareholders or impose senior rights.
- Warrants and dilution: 17.177 million warrants and 4.828 million stock options were outstanding at March 31, 2012 and excluded from diluted loss per share as antidilutive. Cashless warrant exercises after quarter-end resulted in additional share issuance.
- Contingencies: A securities class action related to historical NOV-002 disclosures remained pending after a second amended complaint and motion to dismiss. In the BAM dispute over NOV-002 technology rights, the company had obtained a favorable judgment dismissing BAM’s counterclaims, but BAM appealed. Management did not anticipate a material financial impact from the litigation.
- Other: The company reported $174,254 of Q1 payments to the University of Wisconsin for unrestricted research and clinical-trial costs; its Chief Scientific Officer was a university faculty member. Management stated disclosure controls were effective and identified no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether the proposed financing or another funding transaction closed, and the resulting cash runway, dilution, and financing terms.
- Actual cash burn and clinical-program spending relative to management’s stated mid-Q3 2012 runway.
- Subsequent LIGHT and HOT trial progress, safety and efficacy findings, and whether the planned HOT Phase 2 start occurred.
- Current status and potential financial exposure from the securities litigation and BAM appeal.
- Outstanding shares and potential dilution from warrants and options, including post-quarter-end cashless exercises.
- That Q1 2011 comparatives are historical Cellectar figures, whereas Q1 2012 reflects the combined company.